Martínez-Rubio Antoni, Ascoeta Soledad, Taibi Fadwa, Soldevila Josep Guindo
Department of Cardiology, Parc Taulí University Hospital and Institut d'Investigació i Innovació I3PT, Universitat Autònoma de Barcelona Sabadell, Barcelona, Spain.
Eur Cardiol. 2020 Nov 9;15:e66. doi: 10.15420/ecr.2020.23. eCollection 2020 Feb.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a very contagious virus, has led to the coronavirus disease 2019 (COVID-19) pandemic. The clinical manifestations of this virus in humans vary widely, from asymptomatic to severe, with diverse symptomatology and even death. The substantial transmission from asymptomatic people has facilitated the widespread transmission of SARS-CoV-2, hampering public health initiatives to identify and isolate infected people during the pre-symptomatic contagious period. COVID-19 is associated with cardiac complications that can progress from mild to life-threatening. The aim of this article is to analyse the present knowledge of COVID-19 and cardiac involvement, the development of arrhythmia risk and its treatment.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是一种极具传染性的病毒，它的出现导致了2019冠状病毒病（COVID-19）大流行。这种病毒在人类身上的临床表现差异很大，从无症状到严重症状，症状多样，甚至会导致死亡。无症状感染者的大量传播促进了SARS-CoV-2的广泛传播，阻碍了公共卫生部门在症状出现前的传染期识别和隔离感染者的行动。COVID-19与心脏并发症有关，这些并发症可从轻症发展到危及生命的程度。本文旨在分析目前关于COVID-19及其心脏受累、心律失常风险的发展及其治疗的知识。
